A Clinical Trial of Acyclovir for Viral Uveitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03389191|
Recruitment Status : Recruiting
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
|Condition or disease||Intervention/treatment||Phase|
|Uveitis||Drug: Acyclovir||Not Applicable|
Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, benefits and potential risks. This is a prospective non-comparative interventional study.
Aqueous humor samples were collected from participants to virus detection. Participants will take oral acyclovir 100 mg three times a day and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 12 months to determine efficacy, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Clinical Trial of Oral Acyclovir in Viral Uveitis|
|Actual Study Start Date :||January 2017|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Patients with Viral Uveitis
Oral acyclovir 100 mg three times a day (TID).
- Global assessment of ocular status [ Time Frame: 12 weeks ]Global assessment of ocular status
- Best Corrected Visual Acuity in logMAR [ Time Frame: 12 weeks ]Best Corrected Visual Acuity in logMAR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03389191
|Contact: Xiaomin Zhang, M.D.||+86-13920023990|
|Contact: Jing Yang||+86-13002215386|
|Tianjin Medical University Eye Hospital||Recruiting|
|Tianjin, Tianjin, China, 300000|
|Study Director:||Xiaomin Zhang, M.D.||Tianjin Medical University Eye Hospital|